Cancer Immunology Research · 17 Nov 2026
Circulating TOX+ TIGIT+ CD57+ TEMRA CD8+ T cells are associated with efficacy of combined aPD-L1, aCTLA-4 and metronomic chemotherapy in advanced cervical cancer
Alexandre Bertuccih-index 2, Pauline Maby, Anne Sophie Chrétien, Samuel Granjeaud, Chloé Reine, Amira Ben-Amara, Marie-Sarah Rouvière, Laurent Gorvel, Emilien Billon, Brice Chanez, François Legrand, Claire Cropet, Jean-Sébastien Frenel, Christophe Le Tourneau, Alice Hervieu, Elodie Coquan, Thibault de La Motte Rouge, Esma Saada-Bouzid, Pernelle Lavaud, Julién Hédou, Brice Gaudillière, Aaron Lisberg, Renaud Sabatier, Anthony Gonçalves, Daniel Olive, Philippe Rochigneuxh-index 17
Citations by database
Each database indexes a different set of journals, preprints and books, so they are shown side by side rather than blended.
- OpenCitations0
- Crossref0
- Europe PMC0
Citations per year
The current year is still counting.
- 2026 so far0
Abstract
Abstract To improve ICI efficacy in advanced CC, a promising strategy is to combine anti-PDL-1, anti-CTLA-4 and chemotherapy. The phase I/II MOVIE trial reported a clinical benefit rate of 53.1% of durvalumab, tremelimumab and metronomic oral vinorelbine in patients with pretreated metastatic CC. The objective of this study is to discover immune efficacy biomarkers of this combination. We analyzed 29 advanced CC patients from MOVIE multicentric prospective clinical trial (NCT03518606). We used high-dimensional mass cytometry (CyTOF) to explore the immune landscape in baseline peripheral blood mononuclear cells. We developed 3 immune panels of 40 antibodies (T cells, NK cells and myeloid cells) for the deep-phenotyping of PBMCs. Our bioinformatics workflow of CyTOF data included dimensionality reduction (opt-SNE, UMAP), automated clustering (PhenoGraph) and regression (CITRUS). The biomarker candidates were submitted to a model prediction composed of 11 machine-learning algorithms. In baseline blood samples, high-dimensional analyses consistently identified a population of TOX+TIGIT+CD57+ TEMRA (CD45RA+CCR7-) CD8+ T cells associated with improved clinical outcomes: clinical benefit (CB), progression-free survival (PFS) and overall survival (OS). This population was confirmed by manual gating and 11 machine-learning algorithms. After determining a cut-off at 0.73% of CD45+ cells, patients with an increased blood baseline frequency of TOX+TIGIT+CD57+ TEMRA (CD45RA+CCR7-) CD8+ T cells had an improved CBR (76% vs 25%, p=0.005), an improved PFS (HR=0.35, CI95, 0.13-0.95, p=0.013) and an improved OS (HR=0.19, CI95, 0.07-0.53, p=0.001). Multivariate analysis with classical CC prognostic factors confirmed the OS benefit of our biomarker (HR=0.15, CI95: 0.05-0.47, <0.001).
What the data shows
- No database records a citation yet, as is usual for a paper this new.
- Philippe Rochigneux has the highest h-index among the authors (17).
Graph
This paper in the middle, its authors and their most-cited papers below, the papers it cites to the left and the papers citing it to the right. The timeline lays every paper out by year.
Select a node for its details. Drag to pan, scroll to zoom, drag a node to move it.
Start with
Cited by 0 papers
Who cites this paper, from open citation data, with Crossref's record of each; the 100 newest when there are more.
References (0)
What it cites, from open citation data, with Crossref's record of each.